A new study (and new technology) about quality of life and prostate cancer

Prostate Cancer International and two of its partners — CancerLife and the John Wayne Cancer Institute in Santa Monica, CA — are soon going to be looking for men to participate in a new clinical trial about quality of life and living with prostate cancer. … READ MORE …

SBRT has non-inferior acute and late-term toxicity vs IMRT in two randomized clinical trials

In October 2018, the American Society of Radiation Oncologists (ASTRO) strongly endorsed moderately hypofractionated IMRT (20 or 28 treatments) for primary radiation treatment (see this link). … READ MORE …

Darolutamide (ODM-201) in the treatment of nmCRPC

Also on Thursday in San Francisco, Dr. Karim Fizazi presented the initial results from the ARAMIS trial of darolutamide (formerly known as ODM-201) in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Results from the ARCHES trial presented yesterday in San Francisco

On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …

Much more monitoring of lower risk prostate cancer in US since 2010

According to a brief research letter in the Journal of the American Medical Association this week, there was a major increase in the application of active surveillance (AS) and watchful waiting (WW) in first-line management of prostate cancer between 2010 and 2015. … READ MORE …

What’s on the agenda at the GU Oncology meeting next week?

For those who are interested in what’s going to be on the agenda at the annual Genitourinary Cancers Symposium (to be held in San Francisco starting next Thursday) just click here. … READ MORE …

What patients think and understand can impact their decisions and their outcomes

It has long been appreciated that African-American males have higher risk for diagnosis with prostate cancer, and higher risk for prostate cancer-specific mortality, than those of other ethnic origins living in the US. … READ MORE …